<\/p>\n \u0634\u0631\u0643\u0629 \u0623\u0633\u062a\u0631\u0627\u0644\u064a\u0627 \u0625\u064a\u0641\u0631-\u0628\u0627\u0648\u0631 \u0644\u062a\u0635\u0646\u064a\u0639 \u0622\u0644\u0627\u062a \u0627\u0644\u0646\u0641\u062e \u0628\u0627\u0644\u062d\u0642\u0646 \u0648\u0627\u0644\u062a\u0645\u062f\u064a\u062f \u0627\u0644\u0645\u062d\u062f\u0648\u062f\u0629 - \u0643\u0648\u0646\u062f\u064a\u0644 \u0628\u0627\u0631\u0643\u060c \u0646\u064a\u0648 \u0633\u0627\u0648\u062b \u0648\u064a\u0644\u0632 2200<\/p>\n A technically rigorous guide for pharmaceutical development organisations, clinical research organisations (CROs), and trial packaging operations on how injection stretch blow molding<\/strong> delivers the small-batch production flexibility, batch management precision, drug stability assurance, and contamination prevention that clinical trial investigational medicinal product (IMP) vial packaging requires across Phase I through Phase III of drug development in Australia’s TGA-regulated clinical research environment.<\/p>\n <\/p>\n Clinical trial drug packaging occupies a unique position in the pharmaceutical packaging landscape \u2014 it must meet the same pharmacopoeial material standards and Good Manufacturing Practice requirements as commercial pharmaceutical packaging, while operating at radically different scales (dozens to thousands of units rather than millions), timelines (weeks rather than months for new batches), and operational contexts (investigational medicinal products under regulatory oversight of the TGA’s clinical trials framework rather than commercial product registration). The packaging for clinical trial investigational medicinal products (IMPs) must be good enough to protect the drug and maintain its pharmaceutical quality through the entire trial \u2014 because a packaging failure that compromises drug stability or introduces contamination in a Phase III trial does not merely produce a product recall, it may invalidate months of clinical data and cost the developer tens of millions of dollars in wasted trial investment.<\/p>\n The injection stretch blow molding machine<\/a> serves clinical trial vial packaging through its ability to produce small batches with the same pharmaceutical quality as commercial-scale production, its support for the batch traceability and labelling systems that clinical trial supply chain management requires, and its production flexibility to accommodate the rapid design iterations that characterise the transition from early Phase I to late Phase II and III trial supply. This guide covers the specific technical and regulatory requirements of clinical trial vial packaging for ISBM containers, with specific reference to Australia’s TGA CTN\/CTA clinical trial notification framework.<\/p>\n Australia Ever-Power Injection Stretch Blow Moulding Machine Co., Ltd, based in Condell Park NSW 2200, supports pharmaceutical developers, CROs, and clinical packaging operations with ISBM container solutions for Phase I\u2013III investigational medicinal product supply in the Australian and regional Asia-Pacific clinical research market.<\/p>\n<\/section>\n <\/p>\n <\/p>\n Clinical trial packaging requirements evolve significantly across the phases of drug development \u2014 reflecting both the increasing number of patients and the increasing regulatory scrutiny that characterises the progression from first-in-human Phase I studies through large-scale pivotal Phase III registration trials.<\/p>\n Phase I clinical trials in Australia \u2014 typically conducted at specialist Phase I clinical pharmacology units at major teaching hospitals \u2014 enrol 10\u201380 healthy volunteers or patients in single-ascending-dose (SAD) and multiple-ascending-dose (MAD) studies to characterise the investigational drug’s safety, pharmacokinetics, and early pharmacodynamics. IMP supply volumes for Phase I are very small: a single SAD study cohort (6 active, 2 placebo) may require as few as 50\u2013100 vials per dose level. The primary packaging requirements for Phase I IMP vials are: pharmacopoeial material compliance (the drug formulation used in Phase I is typically an early prototype that may not perfectly represent the final commercial formulation, but the container must meet pharmacopoeial standards); batch documentation sufficient for TGA GMP audits of the Phase I clinical trial; and labelling that meets ICH E11 \/ TGA clinical trial labelling guidance including the mandatory “Investigational Use Only” statement, study code, dose level identifier, storage conditions, and expiry date. Custom bottle design or proprietary packaging features are not relevant at Phase I \u2014 the functional quality and regulatory compliance are all that matters.<\/p>\n Phase II trials in Australia enrol 50\u2013300 patients at specialist clinical sites and assess the drug’s efficacy at defined dose levels in the target patient population. Phase II IMP supply quantities are larger than Phase I \u2014 a 12-week efficacy study with 150 patients each receiving a daily oral liquid dose requires approximately 12,600 vials (150 patients \u00d7 84 days \u00d7 1 vial\/day) at minimum, plus over-supply buffer (typically 20\u201330% additional supply to cover visit variability and patient withdrawals). At these volumes, ISBM container production economics become meaningful \u2014 the cost per unit comparison between ISBM production and high-cost clinical packager sources begins to favour ISBM, particularly when the Phase II trial includes multiple parallel cohorts or dose groups, each requiring separately labelled and batch-identified supply. Phase II also marks the point where clinical trial packaging begins to approach the commercial product packaging concept \u2014 container design decisions made in Phase II are often carried forward to Phase III and potentially to the commercial product, making early Phase II the appropriate stage to consider the commercial container concept alongside the clinical supply requirements.<\/p>\n Phase III pivotal trials \u2014 the final registration-enabling efficacy studies that provide the evidence base for TGA registration \u2014 can enrol hundreds to thousands of patients across multiple Australian and international sites, with trial durations of 1\u20133 years and supply volumes approaching commercial launch quantities. Phase III IMP supply in Australia for multi-national trials is typically managed by global clinical supply operations, but Australian-originated IMP supply (from Australian pharmaceutical manufacturers supplying their own Phase III trials) requires ISBM container production with the full pharmaceutical GMP documentation, stability programme, and container-closure system data that will form the foundation of the eventual TGA CTD registration dossier. The container used for Phase III IMP supply should ideally be identical or closely equivalent to the intended commercial container \u2014 the stability data generated on Phase III IMP supply in the Phase III container is the most clinically relevant data in the TGA registration stability package.<\/p>\n<\/section>\n <\/p>\n The fundamental commercial advantage of ISBM for clinical trial vial supply is small-batch production flexibility \u2014 the ability to produce batches of 500\u201350,000 vials with the same pharmaceutical quality documentation as commercial production, without the minimum order quantity constraints (typically 100,000+ units) that large-scale pharmaceutical container manufacturers impose on commercial production runs. This flexibility is commercially critical for clinical trial supply operations where batch sizes are determined by the trial design, not by production economics.<\/p>\n 500\u20132,000 vials per dose group. Single-cavity ISBM production achieves pharmaceutical GMP documentation with a minimum viable batch of 500 units \u2014 enabling Phase I dose escalation cohorts to receive individually batch-documented vials without the minimum production run waste of large-scale container production. Each batch has full material traceability and IQ\/OQ\/PQ process validation coverage.<\/p>\n<\/div>\n 5,000\u201350,000 vials per production batch. Multi-cavity ISBM tooling (2\u20134 cavities) at single-shift production produces Phase II supply batches within the production economics that Phase II trial budgets support. Recipe-managed production maintains identical process conditions across Phase II production campaigns months apart \u2014 critical for batch-to-batch container consistency throughout a trial.<\/p>\n<\/div>\n 50,000\u2013500,000 vials per production batch, transitioning toward commercial volumes. Multi-cavity 4-station ISBM production generates the container volumes needed for large pivotal Phase III trials while maintaining the process continuity (same validated process recipe) that ensures the Phase III container is demonstrably the same as Phase I\/II, supporting regulatory data bridging in the registration dossier.<\/p>\n<\/div>\n Clinical formulation development often produces container design change requests between trial phases \u2014 different closure system for a modified drug delivery method, modified volume for a reformulated dose. ISBM’s tooling change cycle (2\u20136 weeks for a modified insert) enables rapid container redesign between Phase I and Phase II without the 16\u201324 week offshore tooling lead times that would delay trial schedules.<\/p>\n<\/div>\n<\/div>\n<\/section>\n <\/p>\n <\/p>\n Clinical trial IMP labelling and batch management operate under regulatory requirements that are in some respects more demanding than commercial product labelling \u2014 every clinical trial vial must carry the mandatory ICH\/TGA clinical trial label information (study code, batch number, dose identifier, investigational use only statement, storage conditions, expiry date, and sponsor and trial site information) and must be linked to a chain of custody from container production through IMP filling through distribution to the clinical site and specific patient administration. This chain of custody is the regulatory evidence that the IMP administered to the patient was the product described in the trial documentation \u2014 essential for both the trial’s scientific validity and for the regulatory submission that converts trial data into a TGA marketing approval.<\/p>\n Each production batch of ISBM containers for clinical trial use must have a unique batch number, a batch record documenting the production process parameters and material usage, and a material certificate linking the batch to the specific PET resin and masterbatch lots used. The IMP filler combines the container batch number with the drug substance batch number and the filling process batch number in the finished IMP batch documentation \u2014 creating the multi-component chain of records that regulatory reviewers trace through the clinical trial master file (CTMF) when reviewing the registration dossier. ISBM’s PLC data logging system generates the per-batch process parameter data that feeds into the container batch record without manual data entry \u2014 ensuring the batch record is complete, accurate, and audit-trail protected from post-production modification.<\/p>\n ICH E11 and TGA’s Therapeutic Goods (Therapeutic Goods for Clinical Trials) Order define the mandatory label elements for clinical trial IMP containers. For small-format clinical trial vials, accommodating all mandatory label elements in a legible font size on the available container surface is one of the most challenging practical aspects of clinical trial packaging design. Key mandatory elements that must be on the primary container label (not just the outer carton) include: study sponsor and study code; investigational use only statement; batch number and expiry date; dose strength or concentration; storage conditions; and volume. ISBM’s label panel geometry specification (\u00b10.20mm flatness, \u00b10.30mm width) must be engineered to provide sufficient area for all mandatory elements at a legible font size \u2014 minimum 7-point for standard label text on small vials, with batch number and expiry date at minimum 9-point for reliable readability under clinical site lighting.<\/p>\n Randomised controlled trials \u2014 the gold standard clinical trial design \u2014 use blinding to prevent the placebo effect and investigator bias from confounding the trial results. For double-blind trials, both the patient and the clinical investigator are unaware of whether the patient is receiving active drug or placebo. This blinding requirement extends to the container: the active drug vial and the placebo vial must be visually identical \u2014 same container shape, colour, size, and label format \u2014 so that a clinical site staff member dispensing trial medication cannot identify active versus placebo from the container appearance. ISBM containers for double-blind clinical trials must be produced from the same tooling, the same material specification, and the same process recipe for both the active and placebo presentations \u2014 ensuring that no visual difference in the container itself could break the blind. Random allocation of active versus placebo is achieved through the kit assignment system at the clinical supply packager (using randomisation codes and kit numbers), not through container differences. ISBM’s lot-to-lot production consistency (same tooling, same validated process recipe, same material) provides the container appearance consistency that double-blind trial design requires across multiple production campaigns over a multi-year trial.<\/p>\n<\/section>\n <\/p>\n Ensuring drug stability in clinical trial vials is technically more challenging than in commercial products because: the drug formulation is at an early development stage with limited stability data available; the container-closure system has not yet been through the full commercial validation programme; and the stability requirements for clinical trial IMPs (stability throughout the trial duration under clinical site storage conditions) may extend into conditions that the abbreviated pre-trial stability programme has not yet fully characterised. The consequence of an IMP stability failure \u2014 drug degradation that renders the IMP sub-potent or unsafe \u2014 is trial invalidation, not merely product recall. The cost of an invalidated Phase III trial (typically $20\u2013100 million in direct trial costs) puts the clinical trial vial packaging stability requirement in stark commercial perspective.<\/p>\n The stability programme for clinical trial ISBM vials follows a pragmatic risk-based approach appropriate for the development stage. For Phase I IMP supply \u2014 where the drug formulation is immature and trial duration is short (typically 3\u20136 months) \u2014 a compressed stability programme (real-time stability at 25\u00b0C\/60% RH with accelerated data at 40\u00b0C\/75% RH for 3 months) confirms the container-formulation combination is adequate for the Phase I trial duration and storage conditions, without the complete 24\u201336 month data package that a commercial product requires. For Phase II\/III IMP supply \u2014 where trial durations extend to 1\u20133 years and regulatory scrutiny is higher \u2014 a more complete stability programme aligned with ICH Q1A requirements provides the data foundation that bridges from clinical supply to commercial registration.<\/p>\n The extractables and leachables profile of the ISBM container contributes to drug stability through potential drug-container interactions \u2014 extractable compounds that react with the active pharmaceutical ingredient, catalyse degradation, or affect formulation pH. Early-stage extractables characterisation of the clinical trial ISBM container (conducted during Phase I preparation) provides the data to identify any concerning container-drug interactions before they manifest as stability failures during the trial. Contact sales@isbm-technology.com<\/a> for clinical trial vial stability programme design guidance appropriate for your specific development stage and IMP formulation type.<\/p>\n<\/section>\n <\/p>\n <\/p>\n Contamination prevention for clinical trial ISBM vials operates at two levels: microbial contamination prevention (relevant for sterile IMP presentations) and cross-contamination prevention between different IMP batches or between active and placebo batches in a blinded trial. Both contamination types are particularly consequential in the clinical trial context \u2014 a contamination event in a Phase III trial could compromise the entire trial’s regulatory package, not just the affected batch.<\/p>\n Clinical trial production operations often produce multiple IMPs on shared equipment \u2014 different drugs for different sponsors, or active and placebo presentations for the same trial on the same filling line. Cross-contamination between batches \u2014 even at trace levels \u2014 is a critical GMP concern in the clinical trial context because: the patient populations in clinical trials are often immunocompromised or medically vulnerable; any cross-contamination of an IMP batch could affect both the patient safety and the scientific validity of the trial outcome data; and cross-contamination events trigger regulatory reporting obligations to the TGA under the serious adverse event and IMP defect reporting requirements. The ISBM container production operation must maintain a production changeover protocol between different clinical trial products that prevents container-to-container carryover through the production tooling and environment. ISBM’s clean changeover procedures, documented in the validated manufacturing process and confirmed through residue-swab testing after changeover, provide the evidence of cross-contamination prevention that pharmaceutical GMP auditors require during clinical trial supplier qualification.<\/p>\n Visible and sub-visible particle control in clinical trial vials \u2014 particularly for injectable IMP presentations \u2014 requires the same pharmaceutical GMP production environment and the same container interior surface quality that commercial injectable containers demand. Clinical trial vials for injectable IMPs must meet the same Ph.Eur. visible and sub-visible particle limits as commercial injectable products \u2014 the clinical trial context provides no relaxation of the patient safety-based pharmacopoeial particle limits. ISBM’s ISO Class 7 production environment (where required for injectable vial applications), mirror-polish cavity interior (Ra \u2264 0.05 \u00b5m for injectable vial contact surfaces), and 100% visual inspection of production containers before release to the IMP filler provide the particle control foundation for pharmaceutical GMP injectable clinical trial vial supply. For oral IMP and topical IMP vials where sub-visible particle limits are not pharmacopoeially mandatory, particle control is still required to prevent visible contamination that would fail visual inspection and raise patient safety concerns during clinical site dispensing.<\/p>\n<\/section>\n <\/p>\n Clinical trials in Australia are conducted under the TGA’s Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) schemes, with the ethical oversight of the relevant institutional Human Research Ethics Committee (HREC). The regulatory requirements for IMP packaging under these frameworks are defined by ICH Good Clinical Practice (GCP) guidelines E6(R2), the TGA’s guidance on clinical trial labelling, and the pharmaceutical GMP requirements of the PIC\/S Guide to GMP for Medicinal Products.<\/p>\n
\n\u0642\u0648\u0644\u0628\u0629 \u0627\u0644\u0646\u0641\u062e \u0628\u0627\u0644\u062d\u0642\u0646 \u0648\u0627\u0644\u062a\u0645\u062f\u064a\u062f<\/span>
\nMold Design for ISBM<\/span>
\n\u062a\u0635\u0645\u064a\u0645 \u0627\u0644\u0642\u0648\u0627\u0644\u0628 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0644\u0632\u062c\u0627\u062c\u0627\u062a \u0627\u0644\u0628\u0648\u0644\u064a \u0625\u064a\u062b\u064a\u0644\u064a\u0646 \u062a\u064a\u0631\u064a\u0641\u062b\u0627\u0644\u0627\u062a<\/span><\/div>\n<\/header>\nClinical Trial Packaging: Where Drug Development Rigour Meets Supply Agility<\/h2>\n
![\"Pharmaceutical](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/04\/processed-Pharmaceutical-Bottles-9.webp\")
The Clinical Trial Supply Chain and Its Packaging Requirements by Phase<\/h2>\n
Phase I: First-In-Human \u2014 Minimal Volume, Maximum Flexibility<\/h3>\n
Phase II: Proof of Concept \u2014 Growing Volume, Dose Form Refinement<\/h3>\n
Phase III: Registration-Enabling \u2014 Commercial Scale Transition<\/h3>\n
Small-Batch Production Capability: The Core ISBM Advantage for Clinical Supply<\/h2>\n
Phase I Minimum Batch<\/h4>\n
Phase II Mid-Scale<\/h4>\n
Phase III Scale-Up<\/h4>\n
Rapid Design Iteration<\/h4>\n
![\"Pharmaceutical](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/04\/processed-Pharmaceutical-Bottles-7.webp\")
Batch Management and Labelling for Clinical Trial IMP Supply<\/h2>\n
Batch-Specific Traceability from Container Production<\/h3>\n
Label Panel Specifications for Clinical Trial Labelling<\/h3>\n
Blinded and Double-Blinded Trial Supply Requirements<\/h3>\n
Drug Stability in Clinical Trial Vials: The Development Stage Challenge<\/h2>\n
![\"Clinical](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/04\/processed-Pharmaceutical-Bottles-5.webp\")
Contamination Prevention in Clinical Trial Vial Production and Supply<\/h2>\n
Cross-Contamination Control Between Clinical Trial Batches<\/h3>\n
Particle Control for Clinical Trial IMP Quality<\/h3>\n
TGA Clinical Trial Regulatory Framework and ISBM Container Requirements<\/h2>\n
![\"Clinical](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/04\/processed-Pharmaceutical-Bottles-2.webp\")
![\"ISBM](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/02\/Injection-Stretch-Blow-Molding-Machine-Factory-8.webp\")
![\"Fully](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/02\/Fully-servo-one-step-injection-stretch-blow-molding-machine-four-station-HGYS150-V4-EV-1-2.webp\")
<\/h2>\n![\"Clinical](\"https:\/\/isbm-technology.com\/wp-content\/uploads\/2026\/04\/Pharmaceutical-Bottles-8.webp\")